High materiality9/10
H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)
Why it may matterVerify against the original reporting
very_bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS (analyst target) raises to $344 with current price $239.77; upside potential implied. Direction: bullish.
- Target $344; Price $239.77; upside potential
- Bullish: upside implied from target vs. price
Key facts
- 01
Target: $344
- 02
Posted price: $239.77
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.